ERADICATE
CANNABICS™ RCC-33
COLORECTAL
CANCER (CRC)
- 3rd most commonly diagnosed cancer worldwide
- 1,849,518 new cases in 2018 worldwide
- 2nd most lethal cancer worldwide
- 880,792 deaths in 2018 worldwide
- 67% of treated patients survive 5 years or more
CLINICAL PATH
- Preclinical POC validation (ongoing)
- Dossier preparation for submission of Pre-IND meeting request with FDA
SYNERGISTIC INTERACTION OF RCC-33
ON COLON CANCER CELL LINES
RCC-33: >70% dead cancer cells
CANNABICS™ RCC-33
DRUG CANDIDATE FOR TREATING
COLON CANCER
- A novel cannabinoid-based formulation
- Formula demonstrated significant synergistic antitumor effect
in pre clinical studies - No psychoactive effect
- Patent pending
